Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the Second Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after Second Vaccination;Cohorts 1 and 3: Number of Participants with Adverse Events of Special Interest (AESIs) from the First Vaccination until 2 Years after the Second Vaccination;Cohorts 1 and 3: Number of Participants with Serious Adverse Events (SAEs) from the First Vaccination until 2 Years after the Second Vaccination;Number of Participants with AESIs from ad hoc Booster Vaccination Until the end of the Study;Number of Participants with SAEs from ad hoc Booster Vaccination Until the end of the Study;Number of Participants with Solicited Local AEs for 7 Days after ad hoc Booster Vaccination;Number of Participants with Solicited Systemic AEs for 7 Days after ad hoc Booster Vaccination;Number of Participants with Unsolicited AEs for 28 Days after ad hoc Booster Vaccination

Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the Second Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after Second Vaccination;Cohorts 1 and 3: Number of Participants with Adverse Events of Special Interest (AESIs) from the First Vaccination until 2 Years after the Second Vaccination;Cohorts 1 and 3: Number of Participants with Serious Adverse Events (SAEs) from the First Vaccination until 2 Years after the Second Vaccination;Number of Participants with AESIs from ad hoc Booster Vaccination Until the end of the Study;Number of Participants with SAEs from ad hoc Booster Vaccination Until the end of the Study;Number of Participants with Solicited Local AEs for 7 Days after ad hoc Booster Vaccination;Number of Participants with Solicited Systemic AEs for 7 Days after ad hoc Booster Vaccination;Number of Participants with Unsolicited AEs for 28 Days after ad hoc Booster Vaccination

None

Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the Second Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after Second Vaccination;Cohorts 1 and 3: Number of Participants with Adverse Events of Special Interest (AESIs) from the First Vaccination until 2 Years after the Second Vaccination;Cohorts 1 and 3: Number of Participants with Serious Adverse Events (SAEs) from the First Vaccination until 2 Years after the Second Vaccination;Number of Participants with AESIs from ad hoc Booster Vaccination Until the end of the Study;Number of Participants with SAEs from ad hoc Booster Vaccination Until the end of the Study;Number of Participants with Solicited Local AEs for 7 Days after ad hoc Booster Vaccination;Number of Participants with Solicited Systemic AEs for 7 Days after ad hoc Booster Vaccination;Number of Participants with Unsolicited AEs for 28 Days after ad hoc Booster Vaccination

Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the Second Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after Second Vaccination;Cohorts 1 and 3: Number of Participants with Adverse Events of Special Interest (AESIs) from the First Vaccination until 2 Years after the Second Vaccination;Cohorts 1 and 3: Number of Participants with Serious Adverse Events (SAEs) from the First Vaccination until 2 Years after the Second Vaccination;Number of Participants with AESIs from ad hoc Booster Vaccination Until the end of the Study;Number of Participants with SAEs from ad hoc Booster Vaccination Until the end of the Study;Number of Participants with Solicited Local AEs for 7 Days after ad hoc Booster Vaccination;Number of Participants with Solicited Systemic AEs for 7 Days after ad hoc Booster Vaccination;Number of Participants with Unsolicited AEs for 28 Days after ad hoc Booster Vaccination

Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the Second Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after Second Vaccination;Cohorts 1 and 3: Number of Participants with Adverse Events of Special Interest (AESIs) from the First Vaccination until 2 Years after the Second Vaccination;Cohorts 1 and 3: Number of Participants with Serious Adverse Events (SAEs) from the First Vaccination until 2 Years after the Second Vaccination

Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the Second Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after Second Vaccination;Cohorts 1 and 3: Number of Participants with Adverse Events of Special Interest (AESIs) from the First Vaccination until 2 Years after the Second Vaccination;Cohorts 1 and 3: Number of Participants with Serious Adverse Events (SAEs) from the First Vaccination until 2 Years after the Second Vaccination

Cohort 1 and 3: Number of Participants with Adverse Events of Special Interest (AESIs) from the First Vaccination until 1 Year after the Second Vaccination;Cohort 1 and 3: Number of Participants with Serious Adverse Events (SAEs) from the First Vaccination until 1 Year after the Second Vaccination;Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the Second Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after Second Vaccination

Cohort 1 and 3: Number of Participants with Adverse Events of Special Interest (AESIs) from the First Vaccination until 1 Year after the Second Vaccination;Cohort 1 and 3: Number of Participants with Serious Adverse Events (SAEs) from the First Vaccination until 1 Year after the Second Vaccination;Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with AESIs from the First Vaccination until 6 Months after the Second Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the First Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after Second Vaccination

Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after First Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after Second Vaccination;Cohort 1 and 3: Number of Participants with Serious Adverse Events (SAEs) from the First Vaccination until 1 Year after the Second Vaccination

Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Systemic AEs for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after Second Vaccination;Cohorts 1, 2, and 3: Number of Participants with Unsolicited AEs for 28 Days after First Vaccination;Cohort 2: Number of Participants with SAEs from the First Vaccination until 6 Months after the First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after First Vaccination;Cohorts 1, 2, and 3: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days after Second Vaccination;Cohort 1 and 3: Number of Participants with Serious Adverse Events (SAEs) from the First Vaccination until 1 Year after the Second Vaccination